26 - 27 June 2019, PTB, Braunschweig, Germany
EMPIR project ‘Role of metals and metal containing biomolecules in neurodegenerative diseases such as Alzheimer’s disease’ (15HLT02 ReMiND) is working to improve the accuracy involved in the measurement of biomarkers used to indicate Alzheimer’s disease.
It will establish new reference measurement procedures for established biomarkers in cerebrospinal fluid, found in the brain and spine, while also introducing procedures for potential new blood-based biomarkers.
This will support reliable, comparable measurements in current diagnostic tests and further the development of population-based screening through blood testing, which is urgently required to enable earlier diagnosis of Alzheimer’s disease.
Results from the project will be presented at the Biomolecules in Neurodegenerative Diseases conference next June.
Conference topics will include:
- Reliable quantification of metals in biological matrices
- Reliable quantification of biomolecules in biological matrices
- Role of metals and biomolecules in the development of neurodegenerative diseases
- Importance of comparability in the diagnosis of neurodegenerative diseases
- Registration opens in January 2019, deadline 31 May 2019
- Submission deadline for oral and poster presentations 30 April 2019
This EMPIR project is co-funded by the European Union's Horizon 2020 research and innovation programme and the EMPIR Participating States.
Want to hear more about EURAMET?
Sign up for EURAMET newsletters and other information
Better time synchronisation enables improved service for mobile customers more
Company licences two patent applications; best practice guide available more
30 – 31 May 2019, INRIM, Torino, Italy more
MeterEMI project newsletter available for download more
Presentation on force lever systems for wind turbines wins at IMEKO World Congress more